Pharmacological Treatment of Osteoporosis

作者: Jorge Malouf-Sierra , Roberto Guerri-Fernandez

DOI: 10.5772/30552

关键词:

摘要: Osteoporosis can be classified into two big categories, clinical osteoporosis and densitometric osteoporosis. Clinical involves a fragility fracture, no densitometry is needed to start treatment. Densitometric defined by means of bone mineral density assessment. Treatment should considered depending on the global fracture risk, taking results account. The first step in pharmacological treatment identify whether it primary disease or mass loss secondary another disease. In case osteoporosis, most important step. Pharmacological then if risk too high. purpose reduce fracture. According World Health Organization’s more than half patients suffering do not have (Siris et al., 2004) When any medication started for must remembered that this illness will require long time drug has given conjunction with advise regarding lifestyle changes. It therefore imperative evaluate make decisions based issues such as cost, evaluation cost-efficiency, patient adaptability safety.

参考文章(158)
Diane M Biskobing, Update on bazedoxifene: a novel selective estrogen receptor modulator. Clinical Interventions in Aging. ,vol. 2, pp. 299- 303 ,(2007)
Beighton P, Kretzmar Jh, Hamersma H, Barnard Ah, Sclerosteosis in old age. South African Medical Journal. ,vol. 58, pp. 401- 403 ,(1980)
J.-Y. Reginster, H. W. Minne, O. H. Sorensen, M. Hooper, C. Roux, M. L. Brandi, B. Lund, D. Ethgen, S. Pack, I. Roumagnac, R. Eastell, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporosis International. ,vol. 11, pp. 83- 91 ,(2000) , 10.1007/S001980050010
Writing Group for the Women's Health Initiative Investigators, Writing Group for the Women's Health Initiative Investigators, None, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial JAMA. ,vol. 288, pp. 321- 333 ,(2002) , 10.1001/JAMA.288.3.321
Edward M. Brown, Is the calcium receptor a molecular target for the actions of strontium on bone Osteoporosis International. ,vol. 14, pp. 25- 34 ,(2003) , 10.1007/S00198-002-1343-6
J-Y Reginster, O. Malaise, A. Neuprez, O. Bruyere, Strontium ranelate in the prevention of osteoporotic fractures. International Journal of Clinical Practice. ,vol. 61, pp. 324- 328 ,(2007) , 10.1111/J.1742-1241.2006.01249.X
Dirk M. Anderson, Eugene Maraskovsky, William L. Billingsley, William C. Dougall, Mark E. Tometsko, Eileen R. Roux, Mark C. Teepe, Robert F. DuBose, David Cosman, Laurent Galibert, A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature. ,vol. 390, pp. 175- 179 ,(1997) , 10.1038/36593
Young-Yun Kong, Ulrich Feige, Iidiko Sarosi, Brad Bolon, Anna Tafuri, Sean Morony, Casey Capparelli, Ji Li, Robin Elliott, Susan McCabe, Thomas Wong, Giuseppe Campagnuolo, Erika Moran, Earl R. Bogoch, Gwyneth Van, Linh T. Nguyen, Pamela S. Ohashi, David L. Lacey, Eleanor Fish, William J. Boyle, Josef M. Penninger, Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature. ,vol. 402, pp. 304- 309 ,(1999) , 10.1038/46303
A Lethaby, C Farquhar, A Sarkis, H Roberts, R Jepson, D Barlow, Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding Cochrane Database of Systematic Reviews. ,(1999) , 10.1002/14651858.CD000402
O R Leeuwenkamp, W J van der Vijgh, B C Hüsken, P Lips, J C Netelenbos, Quantification of strontium in plasma and urine with flameless atomic absorption spectrometry. Clinical Chemistry. ,vol. 35, pp. 1911- 1914 ,(1989) , 10.1093/CLINCHEM/35.9.1911